Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Wave Life Sciences Fell as Much as 12.1% This Morning

By Maxx Chatsko - Apr 12, 2017 at 1:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new share offering was announced to raise funds for drug development activities.

What happened

Shares of pre-clinical biopharma Wave Life Sciences (WVE -4.51%) fell nearly 12% in early trading Wednesday after the company announced it will offer 4.2 million shares at $24 apiece. The net proceeds will be approximately $93.4 million and, as is usually the case for share offerings, there's a 30-day option for the underwriters to purchase up to an additional 625,000 shares that could bring in another bounty of $14.1 million in net proceeds. 

The offering will pad a strong end-of-2016 cash position of $150 million and greatly aid the effort to advance the first drug candidates from the company's novel technology platform into clinical trials. As of 1:15 p.m. EDT, the stock had settled to a 12.3% loss.

A man looking at a chart drawn on a chalkboard showing stock losses.

Image source: Getty Images.

So what

There are a few reasons for the share offering. First, Wave Life Sciences has no debt on its balance sheet and there's no reason to start now. It's a young company with a relatively low number of shares outstanding and a strong stock price. Selling shares for cash at this point in the biopharma's life is hardly unexpected.

Second, and most importantly, the company is ramping up development of nucleic acid therapeutics targeting a wide range of rare genetic diseases. Despite their promise, nucleic acid therapeutics have struggled to advance in the clinic due to complex synthesis methods -- something Wave Life Sciences claims to have solved with its novel chemistry platform that focuses on rational design. Proof-of-concept studies have demonstrated the approach results in more stable, active, and specific therapeutic candidates than previous synthesis methods.

While the company has yet to enter a single clinical trial, it currently lists 23 specific disease targets of interest in the discovery phase of development and three drug candidates awaiting to be promoted to phase 1 studies. That includes two targeting Huntington's disease one targeting Duchenne muscular dystrophy. Additionally, last summer Wave Life Sciences partnered with Pfizer to advance nucleic acid therapeutics for rare genetic liver diseases. The collaboration also provides the upstart access to technology from the industry leader that can be applied throughout its pipeline.

Now what

Wave Life Sciences is a young, pre-clinical biopharma armed with proof-of-concept data and a story to tell. Wednesday's share offering will help it advance to the next stage of the development life cycle: clinical trials. There's a long and uncertain road ahead that will include additional future financing from share offerings or debt raises, and maybe more collaboration partners, but that's par for the course. Right now investors should be excited that the company is beginning the next part of its journey.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Wave Life Sciences Ltd. Stock Quote
Wave Life Sciences Ltd.
WVE
$2.54 (-4.51%) $0.12
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.66 (-2.35%) $-1.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.